Type Mutant Stock; Targeted Mutation; Additional information on Genetically Engineered and Mutant Mice. Visit our online Nomenclature tutorial. Mating System Homozygote x Homozygote (Female x Male) 26-DEC-06 Species laboratory mouse Generation [F8p]+F13 (25-MAY-12)
Generation DefinitionsDonating Investigator Dr. Arnon Rosenthal, Rinat Neuroscience Corporation Description
Homozygous null mice are viable, fertile, normal in size and do not display any gross abnormalities. No gene product (mRNA or protein) is detected in brain tissue. A wild-type complement of dopamine neurons, fibers and synaptic terminals is present and the overall brain architecture appears to be intact. They suffer from a reduction in total striatal dopamine and exhibit an attenuated locomotor response when given amphetamine. Normal dopamine release is observed upon stimulation of the nigrostriatal terminal with a single electrical pulse. When multiple stimuli are applied however, null mice exhibit an accelerated recovery of dopamine release. A similar acceleration is seen in wildtype mice in the presence of increased extracellular calcium. The phenotype observed in homozygous Snca-null mice suggests that Snca is an activity-dependent negative regulator of dopamine neurotransmission.Development
A targeting vector containing a neomycin resistance gene driven by a phosphoglycerate 1 promoter was used to disrupt Snca exons 1-2 in RW-4 embryonic stem (ES) cells. These two exons encode amino acids 1-41. Correctly targeted ES cells were injected into C57BL/6 blastocysts and chimeric animals were obtained.
| Control | ||
|---|---|---|
| None Available | ||
| Considerations for Choosing Controls | ||
Parkinson's Disease Models
005987 129-Achetm1Loc/J 007587 129S-Park2tm1Rpa/J 002779 129S-Parp1tm1Zqw/J 017001 129S.B6N-Plk2tm1Elan/J 016198 129S6.Cg-Tg(Camk2a-tTA)1Mmay/JlwsJ 004608 B6(Cg)-Htra2mnd2/J 008133 B6.129-Sncbtm1Sud/J 008084 B6.129P2-Drd4tm1Dkg/J 004744 B6.129P2-Esr1tm1Ksk/J 013586 B6.129P2-Gt(ROSA)26Sortm1Nik/J 002609 B6.129P2-Nos2tm1Lau/J 008843 B6.129P2-Sncgtm1Vlb/J 016566 B6.129S-Hcn1tm2Kndl/J 004322 B6.129S1-Mapk10tm1Flv/J 003190 B6.129S2-Drd2tm1Low/J 006582 B6.129S4-Park2tm1Shn/J 017946 B6.129S4-Pink1tm1Shn/J 005934 B6.129S4-Ucp2tm1Lowl/J 004936 B6.129S6(Cg)-Spp1tm1Blh/J 012453 B6.129X1(FVB)-Lrrk2tm1.1Cai/J 017009 B6.129X1-Nfe2l2tm1Ywk/J 009346 B6.Cg-Lrrk2tm1.1Shn/J 005491 B6.Cg-Mapttm1(EGFP)Klt Tg(MAPT)8cPdav/J 006577 B6.Cg-Park7tm1Shn/J 000567 B6.Cg-T2J +/+ Qkqk-v/J 007004 B6.Cg-Tg(Camk2a-tTA)1Mmay/DboJ 003139 B6.Cg-Tg(DBHn-lacZ)8Rpk/J 007673 B6.Cg-Tg(Gad1-EGFP)3Gfng/J 012466 B6.Cg-Tg(Lrrk2)6Yue/J 012467 B6.Cg-Tg(Lrrk2*G2019S)2Yue/J 008323 B6.Cg-Tg(Mc4r-MAPT/Sapphire)21Rck/J 008321 B6.Cg-Tg(Npy-MAPT/Sapphire)1Rck/J 008324 B6.Cg-Tg(Pmch-MAPT/CFP)1Rck/J 008322 B6.Cg-Tg(Pomc-MAPT/Topaz)1Rck/J 007894 B6.Cg-Tg(Rgs4-EGFP)4Lvt/J 012588 B6.Cg-Tg(TH-ALPP)1Erav/J 012265 B6.Cg-Tg(THY1-SNCA*A30P)TS2Sud/J 008859 B6.Cg-Tg(THY1-SNCA*A53T)F53Sud/J 008135 B6.Cg-Tg(THY1-SNCA*A53T)M53Sud/J 008601 B6.Cg-Tg(Th-cre)1Tmd/J 013583 B6.Cg-Tg(tetO-LRRK2)C7874Cai/J 000544 B6.D2-Cacna1atg/J 012445 B6.FVB-Tg(LRRK2)WT1Mjfa/J 012446 B6.FVB-Tg(LRRK2*G2019S)1Mjfa/J 006660 B6.SJL-Slc6a3tm1.1(cre)Bkmn/J 008364 B6;129-Chattm1(cre/ERT)Nat/J 009688 B6;129-Dbhtm2(Th)Rpa Thtm1Rpa/J 008883 B6;129-Gt(ROSA)26Sortm1(SNCA*A53T)Djmo/TmdJ 008889 B6;129-Gt(ROSA)26Sortm2(SNCA*119)Djmo/TmdJ 008886 B6;129-Gt(ROSA)26Sortm3(SNCA*E46K)Djmo/TmdJ 009347 B6;129-Lrrk2tm1.1Shn/J 016209 B6;129-Lrrk2tm2.1Shn/J 016210 B6;129-Lrrk2tm3.1Shn/J 013050 B6;129-Pink1tm1Aub/J 004807 B6;129-Psen1tm1Mpm Tg(APPSwe,tauP301L)1Lfa/Mmjax 006390 B6;129-Sncatm1Sud Sncbtm1.1Sud/J 008532 B6;129-Thtm1(cre/Esr1)Nat/J 008333 B6;129P2-Dldtm1Ptl/J 008333 B6;129P2-Dldtm1Ptl/J 002596 B6;129P2-Nos2tm1Lau/J 003243 B6;129S-Tnfrsf1atm1Imx Tnfrsf1btm1Imx/J 016575 B6;C3-Tg(PDGFB-LRRK2*G2019S)340Djmo/J 016576 B6;C3-Tg(PDGFB-LRRK2*R1441C)574Djmo/J 008169 B6;C3-Tg(Prnp-MAPT*P301S)PS19Vle/J 004479 B6;C3-Tg(Prnp-SNCA*A53T)83Vle/J 000231 B6;C3Fe a/a-Csf1op/J 012450 B6;D2-Tg(tetO-SNCA)1Cai/J 013725 B6;SJL-Tg(LRRK2)66Mjff/J 016555 B6;SJL-Tg(Nqo1-ALPP)1Jaj/J 008473 B6;SJL-Tg(THY1-SNCA*A30P)M30Sud/J 008134 B6;SJL-Tg(THY1-SNCA*A30P)TS2Sud/J 016976 B6C3-Tg(tetO-SNCA*A53T)33Vle/J 000506 B6C3Fe a/a-Qkqk-v/J 003741 B6D2-Tg(Prnp-MAPT)43Vle/J 018768 B6N.Cg-Tg(SNCA*E46K)3Elan/J 012621 C.129S(B6)-Chrna3tm1.1Hwrt/J 016120 C57BL/6-Lrrk1tm1.1Mjff/J 012444 C57BL/6-Lrrk2tm1Mjfa/J 008389 C57BL/6-Tg(THY1-SNCA)1Sud/J 012769 C57BL/6-Tg(Thy1-Sncg)HvP36Putt/J 005706 C57BL/6-Tg(tetO-CDK5R1/GFP)337Lht/J 006618 C57BL/6-Tg(tetO-COX8A/EYFP)1Ksn/J 008245 C57BL/6J-Tg(Th-SNCA)5Eric/J 008239 C57BL/6J-Tg(Th-SNCA*A30P*A53T)39Eric/J 016122 C57BL/6N-Lrrk1tm1.1Mjff Lrrk2tm1.1Mjff/J 016121 C57BL/6N-Lrrk2tm1.1Mjff/J 016123 C57BL/6N-Sncatm1Mjff/J 016936 C57BL/6N-Tg(Thy1-SNCA)12Mjff/J 017682 C57BL/6N-Tg(Thy1-SNCA)15Mjff/J 007677 CB6-Tg(Gad1-EGFP)G42Zjh/J 009610 FVB/N-Tg(LRRK2)1Cjli/J 009609 FVB/N-Tg(LRRK2*G2019S)1Cjli/J 009604 FVB/N-Tg(LRRK2*R1441G)135Cjli/J 009090 FVB/NJ-Tg(Slc6a3-PARK2*Q311X)AXwy/J 017678 FVB;129-Pink1tm1Aub Tg(Prnp-SNCA*A53T)AAub/J 017744 FVB;129-Tg(Prnp-SNCA*A53T)AAub/J 010710 FVB;129S6-Sncatm1Nbm Tg(SNCA)1Nbm/J 010788 FVB;129S6-Sncatm1Nbm Tg(SNCA*A30P)1Nbm Tg(SNCA*A30P)2Nbm/J 010799 FVB;129S6-Sncatm1Nbm Tg(SNCA*A53T)1Nbm Tg(SNCA*A53T)2Nbm/J 004808 STOCK Mapttm1(EGFP)Klt Tg(MAPT)8cPdav/J 000942 STOCK Pitx3ak/2J 014092 STOCK Tg(ACTB-tTA2,-MAPT/lacZ)1Luo/J 006340 STOCK Tg(Gad1-EGFP)98Agmo/J 017000 STOCK Tg(SNCA*E46K)3Elan/J 008474 STOCK Tg(THY1-SNCA*A53T)F53Sud/J 008132 STOCK Tg(THY1-Snca)M1mSud/J 012441 STOCK Tg(tetO-LRRK2*G2019S)E3Cai/J 012442 STOCK Tg(tetO-SNCA*A53T)E2Cai/J 012449 STOCK Tg(teto-LRRK2)C7874Cai/J View Parkinson's Disease Models (109 strains)
Strains carrying other alleles of Snca
006390 B6;129-Sncatm1Sud Sncbtm1.1Sud/J 016123 C57BL/6N-Sncatm1Mjff/J 010710 FVB;129S6-Sncatm1Nbm Tg(SNCA)1Nbm/J 010788 FVB;129S6-Sncatm1Nbm Tg(SNCA*A30P)1Nbm Tg(SNCA*A30P)2Nbm/J 010799 FVB;129S6-Sncatm1Nbm Tg(SNCA*A53T)1Nbm Tg(SNCA*A53T)2Nbm/J 008132 STOCK Tg(THY1-Snca)M1mSud/J View Strains carrying other alleles of Snca (6 strains)
Visit the Parkinson's Disease Resource site for helpful information on Parkinson's and research resources.
View Related Disease (OMIM) Terms
Related Disease (OMIM) Terms provided by MGI
- Model with phenotypic similarity to human disease where etiologies involve orthologs. Human genes are associated with this disease. Orthologs of those genes appear in the mouse genotype(s).
Parkinson Disease 1, Autosomal Dominant; PARK1
- Potential model based on gene homology relationships. Phenotypic similarity to the human disease has not been tested. Dementia, Lewy Body; DLB (SNCA)
Parkinson Disease 4, Autosomal Dominant; PARK4 (SNCA)
View Mammalian Phenotype Terms
Mammalian Phenotype Terms provided by MGI
assigned by genotype
Sncatm1Rosl/Sncatm1Rosl
involves: 129X1/SvJ * C57BL/6
- nervous system phenotype
- abnormal dopaminergic neuron morphology
- when exposed to paired electrical stimuli, striatal brain slices (containing dopamine terminals) from homozygous mice exhibit a faster dopamine release recovery as compared to wild-type (MGI Ref ID J:60151)
- dopamine discharge and reuptake in response to a single electrical pulse or a train of pulses is comparable to wild-type (MGI Ref ID J:60151)
- decreased dopamine level
- dopamine content is reduced by 18% in the striatum, however, dopamine content in the ventral midbrain and nucleus accumbens is similar to wild-type (MGI Ref ID J:60151)
- behavior/neurological phenotype
- abnormal locomotor activation
- homeostasis/metabolism phenotype
- decreased dopamine level
- dopamine content is reduced by 18% in the striatum, however, dopamine content in the ventral midbrain and nucleus accumbens is similar to wild-type (MGI Ref ID J:60151)
The following phenotype information may relate to a genetic background differing from this JAX® Mice strain.
Sncatm1Rosl/Sncatm1Rosl
involves: 129X1/SvJ
- immune system phenotype
- decreased susceptibility to bacterial infection
- mice do not exhibit as much dopamine neuron loss following injection of LPS into the substantia nigra as similarly treated wild-type mice (MGI Ref ID J:138194)
Sncatm1Rosl/Sncatm1Rosl
B6.129X1-Sncatm1Rosl
- nervous system phenotype
- *normal* nervous system phenotype
- at P2, homozygotes display normal numbers of sensory neurons in trigeminal ganglia and L6 lumbar dorsal root ganglia relative to wild-type controls (MGI Ref ID J:86439)
- homozygotes exhibit normal morphology and numbers of myelinated A-fibers and unmyelinated C-fibers in adult saphenous nerves relative to wild-type controls (MGI Ref ID J:86439)
- in culture, neurons from P2 peripheral (trigeminal and superior cervical) ganglia of mutant mice display the same survival rate as wild-type neurons in the presence of nerve growth factor and, as expected, fail to survive in its absence (MGI Ref ID J:86439)
- homozygotes display no gross abnormalities of the nervous system relative to wild-type controls (MGI Ref ID J:92213)
- no significant differences in dopamine or its metabolite (DOPAC, 5-HIAA and HVA) levels are noted in the striatum at 9 months of age (MGI Ref ID J:92213)
- decreased dopaminergic neuron number
- adult homozygotes show a ~20% reduction in the number of tyrosine hydroxylase (TH)-positive dopaminergic neurons in substantia nigra pars compacta (SNpc) but not in ventral tegmental area (VTA) relative to wild-type controls, similar to that observed in adult Sncgtm1Vlb homozygotes (MGI Ref ID J:92213)
- however, no significant decrease in the number of TH-positive dopaminergic neurons is observed in SNpc after methyl-phenyl-tetrahydropyridine (MPTP) treatment relative to controls (MGI Ref ID J:92213)
- decreased susceptibility to dopaminergic neuron neurotoxicity
- homozygotes display resistance of SNpc dopaminergic neurons to MPTP neurotoxicity (MGI Ref ID J:92213)
- homeostasis/metabolism phenotype
- decreased susceptibility to dopaminergic neuron neurotoxicity
- homozygotes display resistance of SNpc dopaminergic neurons to MPTP neurotoxicity (MGI Ref ID J:92213)
- behavior/neurological phenotype
- *normal* behavior/neurological phenotype
- homozygotes are behaviorally normal and show no detectable motor dysfunction in either constant speed or accelerating rotarod tests (MGI Ref ID J:92213)
- cellular phenotype
- decreased susceptibility to dopaminergic neuron neurotoxicity
- homozygotes display resistance of SNpc dopaminergic neurons to MPTP neurotoxicity (MGI Ref ID J:92213)
View Research Applications
Research Applications
This mouse can be used to support research in many areas including:
Sncatm1Rosl relatedNeurobiology Research
Parkinson's Disease
resistance to MPTP
synuclein mutants
Neurobiology Research
Astrocyte Defects
Behavioral and Learning Defects
Neurodegeneration
Neurotransmitter Receptor and Synaptic Vesicle Defects
| Allele Symbol | Sncatm1Rosl | ||
|---|---|---|---|
| Allele Name | targeted mutation 1, Arnon Rosenthal | ||
| Allele Type | Targeted (knock-out) | ||
| Common Name(s) | alpha-Syn-; alpha-Synko; | ||
| Strain of Origin | 129X1/SvJ | ||
| ES Cell Line Name | RW-4 | ||
| ES Cell Line Strain | 129X1/SvJ | ||
| Gene Symbol and Name | Snca, synuclein, alpha | ||
| Chromosome | 6 | ||
| Gene Common Name(s) | NACP; PARK1; PARK4; PD1; alpha-synuclein; alphaSYN; | ||
| Molecular Note | A PGK-neo cassette was used to delete exons 1 and 2, encoding amino acids 1 through 41 as well as a 5' untranslated region. RT-PCR analysis of extracts from the brains of homozygous mutant mice, using probes for both the deleted 5' region as well the untargeted 3' region, showed an absence of transcript. Western blot analysis, immunohistochemical analysis, and in situ hybridization confirmed a lack of encoded protein in homozygous mutant mice. [MGI Ref ID J:60151] | ||
Genotyping Protocols
Sncatm1Rosl,SEPARATED MELT
Sncatm1Rosl, Separated PCR
Helpful Links
Genotyping resources and troubleshooting
Abeliovich A; Schmitz Y; Farinas I; Choi-Lundberg D; Ho WH; Castillo PE; Shinsky N; Verdugo JM; Armanini M; Ryan A; Hynes M; Phillips H; Sulzer D; Rosenthal A. 2000. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25(1):239-52. [PubMed: 10707987] [MGI Ref ID J:60151]
Sncatm1Rosl relatedAkil O; Weber CM; Park SN; Ninkina N; Buchman V; Lustig LR. 2008. Localization of synucleins in the Mammalian cochlea. J Assoc Res Otolaryngol 9(4):452-63. [PubMed: 18665422] [MGI Ref ID J:141972]
Al-Wandi A; Ninkina N; Millership S; Williamson SJ; Jones PA; Buchman VL. 2010. Absence of alpha-synuclein affects dopamine metabolism and synaptic markers in the striatum of aging mice. Neurobiol Aging 31(5):796-804. [PubMed: 19097673] [MGI Ref ID J:159589]
Alvarez-Fischer D; Henze C; Strenzke C; Westrich J; Ferger B; Hoglinger GU; Oertel WH; Hartmann A. 2008. Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice. Exp Neurol 210(1):182-93. [PubMed: 18053987] [MGI Ref ID J:134020]
Anwar S; Peters O; Millership S; Ninkina N; Doig N; Connor-Robson N; Threlfell S; Kooner G; Deacon RM; Bannerman DM; Bolam JP; Chandra SS; Cragg SJ; Wade-Martins R; Buchman VL. 2011. Functional alterations to the nigrostriatal system in mice lacking all three members of the synuclein family. J Neurosci 31(20):7264-74. [PubMed: 21593311] [MGI Ref ID J:173360]
Cano-Jaimez M; Perez-Sanchez F; Milan M; Buendia P; Ambrosio S; Farinas I. 2010. Vulnerability of peripheral catecholaminergic neurons to MPTP is not regulated by alpha-synuclein. Neurobiol Dis 38(1):92-103. [PubMed: 20079841] [MGI Ref ID J:159933]
Chadchankar H; Ihalainen J; Tanila H; Yavich L. 2011. Decreased reuptake of dopamine in the dorsal striatum in the absence of alpha-synuclein. Brain Res 1382:37-44. [PubMed: 21276428] [MGI Ref ID J:170114]
Chadchankar H; Yavich L. 2011. Sub-regional differences and mechanisms of the short-term plasticity of dopamine overflow in striatum in mice lacking alpha-synuclein. Brain Res 1423:67-76. [PubMed: 22000591] [MGI Ref ID J:179023]
Duka T; Rusnak M; Drolet RE; Duka V; Wersinger C; Goudreau JL; Sidhu A. 2006. Alpha-synuclein induces hyperphosphorylation of Tau in the MPTP model of parkinsonism. FASEB J 20(13):2302-12. [PubMed: 17077307] [MGI Ref ID J:129746]
Ebadi M; Sharma S. 2006. Metallothioneins 1 and 2 attenuate peroxynitrite-induced oxidative stress in Parkinson disease. Exp Biol Med (Maywood) 231(9):1576-83. [PubMed: 17018883] [MGI Ref ID J:129277]
Gao HM; Kotzbauer PT; Uryu K; Leight S; Trojanowski JQ; Lee VM. 2008. Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. J Neurosci 28(30):7687-98. [PubMed: 18650345] [MGI Ref ID J:138194]
Geng X; Lou H; Wang J; Li L; Swanson AL; Sun M; Beers-Stolz D; Watkins S; Perez RG; Drain P. 2011. alpha-Synuclein binds the K(ATP) channel at insulin-secretory granules and inhibits insulin secretion. Am J Physiol Endocrinol Metab 300(2):E276-86. [PubMed: 20858756] [MGI Ref ID J:172332]
Klivenyi P; Siwek D; Gardian G; Yang L; Starkov A; Cleren C; Ferrante RJ; Kowall NW; Abeliovich A; Beal MF. 2006. Mice lacking alpha-synuclein are resistant to mitochondrial toxins. Neurobiol Dis 21(3):541-8. [PubMed: 16298531] [MGI Ref ID J:106226]
Kokhan VS; Afanasyeva MA; Van'kin GI. 2012. alpha-Synuclein knockout mice have cognitive impairments. Behav Brain Res 231(1):226-30. [PubMed: 22469626] [MGI Ref ID J:185435]
Lou H; Montoya SE; Alerte TN; Wang J; Wu J; Peng X; Hong CS; Friedrich EE; Mader SA; Pedersen CJ; Marcus BS; McCormack AL; Di Monte DA; Daubner SC; Perez RG. 2010. Serine 129 phosphorylation reduces the ability of alpha-synuclein to regulate tyrosine hydroxylase and protein phosphatase 2A in vitro and in vivo. J Biol Chem 285(23):17648-61. [PubMed: 20356833] [MGI Ref ID J:164560]
Luk KC; Kehm V; Carroll J; Zhang B; O'Brien P; Trojanowski JQ; Lee VM. 2012. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338(6109):949-53. [PubMed: 23161999] [MGI Ref ID J:191204]
Luk KC; Kehm VM; Zhang B; O'Brien P; Trojanowski JQ; Lee VM. 2012. Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. J Exp Med 209(5):975-86. [PubMed: 22508839] [MGI Ref ID J:185142]
Martin ED; Gonzalez-Garcia C; Milan M; Farinas I; Cena V. 2004. Stressor-related impairment of synaptic transmission in hippocampal slices from alpha-synuclein knockout mice. Eur J Neurosci 20(11):3085-91. [PubMed: 15579163] [MGI Ref ID J:101275]
Martin-Clemente B; Alvarez-Castelao B; Mayo I; Sierra AB; Diaz V; Milan M; Farinas I; Gomez-Isla T; Ferrer I; Castano JG. 2004. alpha-Synuclein expression levels do not significantly affect proteasome function and expression in mice and stably transfected PC12 cell lines. J Biol Chem 279(51):52984-90. [PubMed: 15466467] [MGI Ref ID J:118517]
Mosharov EV; Larsen KE; Kanter E; Phillips KA; Wilson K; Schmitz Y; Krantz DE; Kobayashi K; Edwards RH; Sulzer D. 2009. Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons. Neuron 62(2):218-29. [PubMed: 19409267] [MGI Ref ID J:155071]
Ninkina N; Papachroni K; Robertson DC; Schmidt O; Delaney L; O'Neill F; Court F; Rosenthal A; Fleetwood-Walker SM; Davies AM; Buchman VL. 2003. Neurons expressing the highest levels of gamma-synuclein are unaffected by targeted inactivation of the gene. Mol Cell Biol 23(22):8233-45. [PubMed: 14585981] [MGI Ref ID J:86439]
Papachroni K; Ninkina N; Wanless J; Kalofoutis AT; Gnuchev NV; Buchman VL. 2005. Peripheral sensory neurons survive in the absence of alpha- and gamma-synucleins. J Mol Neurosci 25(2):157-64. [PubMed: 15784963] [MGI Ref ID J:121324]
Pelkonen A; Yavich L. 2011. Neuromuscular pathology in mice lacking alpha-synuclein. Neurosci Lett 487(3):350-3. [PubMed: 21029764] [MGI Ref ID J:168149]
Rappley I; Myers DS; Milne SB; Ivanova PT; Lavoie MJ; Brown HA; Selkoe DJ. 2009. Lipidomic profiling in mouse brain reveals differences between ages and genders, with smaller changes associated with alpha-synuclein genotype. J Neurochem 111(1):15-25. [PubMed: 19627450] [MGI Ref ID J:153557]
Reznichenko L; Cheng Q; Nizar K; Gratiy SL; Saisan PA; Rockenstein EM; Gonzalez T; Patrick C; Spencer B; Desplats P; Dale AM; Devor A; Masliah E. 2012. In vivo alterations in calcium buffering capacity in transgenic mouse model of synucleinopathy. J Neurosci 32(29):9992-8. [PubMed: 22815513] [MGI Ref ID J:186464]
Robertson DC; Schmidt O; Ninkina N; Jones PA; Sharkey J; Buchman VL. 2004. Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of gamma-synuclein, alpha-synuclein and double alpha/gamma-synuclein null mutant mice. J Neurochem 89(5):1126-36. [PubMed: 15147505] [MGI Ref ID J:92213]
Scott D; Roy S. 2012. alpha-Synuclein Inhibits Intersynaptic Vesicle Mobility and Maintains Recycling-Pool Homeostasis. J Neurosci 32(30):10129-35. [PubMed: 22836248] [MGI Ref ID J:186545]
Senior SL; Ninkina N; Deacon R; Bannerman D; Buchman VL; Cragg SJ; Wade-Martins R. 2008. Increased striatal dopamine release and hyperdopaminergic-like behaviour in mice lacking both alpha-synuclein and gamma-synuclein. Eur J Neurosci 27(4):947-57. [PubMed: 18333965] [MGI Ref ID J:132938]
Sharon R; Bar-Joseph I; Mirick GE; Serhan CN; Selkoe DJ. 2003. Altered fatty acid composition of dopaminergic neurons expressing alpha-synuclein and human brains with alpha-synucleinopathies. J Biol Chem 278(50):49874-81. [PubMed: 14507911] [MGI Ref ID J:118570]
Tomas-Zapico C; Diez-Zaera M; Ferrer I; Gomez-Ramos P; Moran MA; Miras-Portugal MT; Diaz-Hernandez M; Lucas JJ. 2012. alpha-Synuclein accumulates in huntingtin inclusions but forms independent filaments and its deficiency attenuates early phenotype in a mouse model of Huntington's disease. Hum Mol Genet 21(3):495-510. [PubMed: 22045698] [MGI Ref ID J:179713]
Animal Health Reports
Room Number AX11
Colony Maintenance
Breeding & Husbandry This strain arose on a B6;129X background. It is maintained on a B6;129X background. Coat color expected from breeding:Black or Agouti Mating System Homozygote x Homozygote (Female x Male) 26-DEC-06 Diet Information LabDiet® 5K52/5K67
| Pricing for USA, Canada and Mexico shipping destinations |
|
Price per mouse (US dollars $) Gender Genotypes Provided Individual Mouse $177.00 Female or Male Homozygous for Sncatm1Rosl
Price per Pair (US dollars $) Pair Genotype $354.00 Homozygous for Sncatm1Rosl x Homozygous for Sncatm1Rosl Standard Supply
Repository-Live. Repository-Live represents an exclusive set of over 1500 unique mouse models maintained at The Jackson Laboratory to support a vast array of research areas. The breeding colonies for Repository Strains provide mice for both large and small orders and fluctuate in size depending on current demand for each strain. Repository-live orders are treated as custom orders. Within 2 business days, we respond to each availability inquiry or order with various delivery options. Repository Strains typically are delivered at 4 to 8 weeks of age and will not exceed 12 weeks of age on the day of shipping.
| Pricing for International shipping destinations |
|
Price per mouse (US dollars $) Gender Genotypes Provided Individual Mouse $230.10 Female or Male Homozygous for Sncatm1Rosl
Price per Pair (US dollars $) Pair Genotype $460.20 Homozygous for Sncatm1Rosl x Homozygous for Sncatm1Rosl Standard Supply
Repository-Live. Repository-Live represents an exclusive set of over 1500 unique mouse models maintained at The Jackson Laboratory to support a vast array of research areas. The breeding colonies for Repository Strains provide mice for both large and small orders and fluctuate in size depending on current demand for each strain. Repository-live orders are treated as custom orders. Within 2 business days, we respond to each availability inquiry or order with various delivery options. Repository Strains typically are delivered at 4 to 8 weeks of age and will not exceed 12 weeks of age on the day of shipping.
|
|
Repository-Live. Repository-Live represents an exclusive set of over 1500 unique mouse models maintained at The Jackson Laboratory to support a vast array of research areas. The breeding colonies for Repository Strains provide mice for both large and small orders and fluctuate in size depending on current demand for each strain. Repository-live orders are treated as custom orders. Within 2 business days, we respond to each availability inquiry or order with various delivery options. Repository Strains typically are delivered at 4 to 8 weeks of age and will not exceed 12 weeks of age on the day of shipping.
| Control | ||
|---|---|---|
| None Available | ||
| Considerations for Choosing Controls | ||
| Control Pricing Information for Genetically Engineered Mutant Strains. | ||
For Licensing and Use Restrictions view the link(s) below:
- Use of MICE by companies or for-profit entities requires a license prior to shipping.
| phone: | 207-288-6470 |
| fax: | 207-288-6655 |
MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.
In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.
In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.
MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.
The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.
Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.